The RB tumor suppressor positively regulates transcription of the anti-angiogenic protein NOL7

Neoplasia (United States)

Volumn 14, Issue 12, 2012, Pages 1213-1222

  Mankame, Tanmayi P ^a   Lingen, Mark W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; NUCLEAR PROTEIN; NUCLEAR PROTEIN 7; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; RETINOBLASTOMA PROTEIN; RNA POLYMERASE II; STREPTAVIDIN; TAMOXIFEN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL CYCLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEOPLASM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

EID: 84871592736     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121422     Document Type: Article

References (62)

1. Folkman J (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82, 4-6.
2. Folkman J and Hanahan D (1991). Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 22, 339-347.
3. Grépin R and Pagès G (2010). Molecular mechanisms of resistance to tumour anti-angiogenic strategies. J Oncol 2010, 835680.
4. Weis SM and Cheresh DA (2011). Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17, 1359-1370.
5. Bergers G and Hanahan D (2008). Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8, 592-603.
6. Hasina R, Pontier AL, Fekete MJ, Martin LE, Qi XM, Brigaudeau C, Pramanik R, Cline EI, Coignet LJ, and Lingen MW (2006). NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype. Oncogene 25, 588-598.
7. Doçi CL, Zhou G, and Lingen MW (in revision). The novel tumor suppressor NOL7 post-transcriptionally regulates thrombospondin-1 expression. Oncogene.
8. Doçi CL, Mankame TP, Langerman A, Ostler KR, Kanteti R, Best T, Onel K, Godley LA, Salgia R, and Lingen MW (2012). Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. Int J Gynecol Pathol 31, 15-24.
9. Huang L, Zheng M, Zhou Q-M, Zhang M-Y, Yu Y-H, Yun J-P, and Wang H-Y (2012). Identification of a 7-gene signature that predicts relapse and survival for early stage patients with cervical carcinoma. Med Oncol 29, 2911-2918.
10. Rader JS, Gerhard DS, O'Sullivan MJ, Li Y, Li L, Liapis H, and Huettner PC (1998). Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p. Genes Chromosomes Cancer 22, 57-65.
11. Zhang Z, Borecki I, Nguyen L, Ma D, Smith K, Huettner PC, Mutch DG, Herzog TJ, Gibb RK, Powell MA, et al. (2007). CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res 67, 11202-11208.
12. Mankame TP, Zhou G, and Lingen MW (2010). Identification and characterization of the human NOL7 gene promoter. Gene 456, 36-44.
13. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, and Tommasino M (2009). The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 40, 1-13.
14. Chen W, Li F, Mead L, White H, Walker J, Ingram DA, and Roman A (2007). Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. Virology 367, 168-174.
15. Burkhart DL and Sage J (2008). Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8, 671-682.
16. Moody CA and Laimins LA (2010). Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10, 550-560.
17. Nam EJ, Kim JW, Kim SW, Kim YT, Kim JH, Yoon BS, Cho NH, and Kim S (2007). The expressions of the Rb pathway in cervical intraepithelial neoplasia; predictive and prognostic significance. Gynecol Oncol 104, 207-211.
18. Johung K, Goodwin EC, and DiMaio D (2007). Human papillomavirus E7 repression in cervical carcinoma cells initiates a transcriptional cascade driven by the retinoblastoma family, resulting in senescence. J Virol 81, 2102-2116.
19. Decesse JT, Medjkane S, Datto MB, and Cremisi CE (2001). RB regulates transcription of the p21/WAF1/CIP1 gene. Oncogene 20, 962-971.
20. Ianari A, Natale T, Calo E, Ferretti E, Alesse E, Screpanti I, Haigis K, Gulino A, and Lees JA (2009). Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell 15, 184-194.
21. Howley P, Scheffner M, Huibregtse J, and Münger K (1991). Oncoproteins encoded by the cancer-associated human papillomaviruses target the products of the retinoblastoma and p53 tumor suppressor genes. Cold Spring Harb Symp Quant Biol 56, 149-155.
22. Liu X, Roberts J, Dakic A, Zhang Y, and Schlegel R (2008). HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology 375, 611-623.
23. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, et al. (2003). Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9, 493-501.
24. Dirlam A, Spike BT, and Macleod KF (2007). Deregulated E2f-2 underlies cell cycle and maturation defects in retinoblastoma null erythroblasts. Mol Cell Biol 27, 8713-8728.
25. Flowers S, Beck GR, and Moran E (2010). Transcriptional activation by pRB and its coordination with SWI/SNF recruitment. Cancer Res 70, 8282-8287.
26. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, Aunis D, and Rohr O (2007). Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 26, 412-423.
27. Vieira KF, Levings PP, Hill MA, Crusselle VJ, Kang SH, Engel JD, and Bungert J (2004). Recruitment of transcription complexes to the β-globin gene locus in vivo and in vitro. J Biol Chem 279, 50350-50357.
28. Deng W-G, Zhu Y, Montero A, and Wu KK (2003). Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin-agarose pulldown assay. Anal Biochem 323, 12-18.
29. Wu KK (2006). Analysis of protein-DNA binding by streptavidin-agarose pulldown. Methods Mol Biol 338, 281-290.
30. Darnell GA, Schroder WA, Antalis TM, Lambley E, Major L, Gardner J, Birrell G, Cid-Arregui A, and Suhrbier A (2007). Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. J Biol Chem 282, 37492-37500.
31. Lehman TA, Modali R, Boukamp P, Stanek J, Bennett WP, Welsh JA, Metcalf RA, Stampfer MR, Fusenig N, Rogan EM, et al. (1993). p53 Mutations in human immortalized epithelial cell lines. Carcinogenesis 14, 833-839.
32. Macleod KF, Hu Y, and Jacks T (1996). Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J 15, 6178-6188.
33. Phelps WC, Yee CL, Munger K, and Howley PM (1988). The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53, 539-547.
34. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, and Matlashewski G (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19, 1092-1100.
35. Murai Y, Hayashi S, Takahashi H, Tsuneyama K, and Takano Y (2005). Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines. Pathol Res Pract 201, 109-115.
36. Morris EJ and Dyson NJ (2001). Retinoblastoma protein partners. Adv Cancer Res 82, 1-54.
37. Trimarchi JM and Lees JA (2002). Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3, 11-20.
38. Werner T (2000). Computer-assisted analysis of transcription control regions. Matinspector and other programs. Methods Mol Biol 132, 337-349.
39. Farre D, Roset R, Huerta M, Adsuara JE, Rosello L, Alba MM, and Messeguer X (2003). Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucl Acids Res 31, 3651-3653.
40. Chen P-L, Scully P, Shew J-Y, Wang JYJ, and Lee W-H (1989). Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58, 1193-1198.
41. Burke JR, Deshong AJ, Pelton JG, and Rubin SM (2010). Phosphorylationinduced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding. J Biol Chem 285, 16286-16293.
42. Lundberg AS and Weinberg RA (1998). Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclincdk complexes. Mol Cell Biol 18, 753-761.
43. Knudsen ES and Wang JY (1997). Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 17, 5771-5783.
44. Connell-Crowley L, Harper JW, and Goodrich DW (1997). Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 8, 287-301.
45. Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, and Harlow E (1991). The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J 10, 4279-4290.
46. Lee EY, Cam H, Ziebold U, Rayman JB, Lees JA, and Dynlacht BD (2002). E2F4 loss suppresses tumorigenesis in Rb mutant mice. Cancer Cell 2, 463-472.
47. Fiedler M, Müller-Holzner E, Viertler H-P, Widschwendter A, Laich A, Pfister G, Spoden GA, Jansen-Dürr P, and Zwerschke W (2004). High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. FASEB J 18, 1120-1122.
48. Wiest T, Schwarz E, Enders C, Flechtenmacher C, and Bosch FX (2002). Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21, 1510-1517.
49. Yuan J, Knorr J, Altmannsberger M, Goeckenjan G, Ahr A, Scharl A, and Strebhardt K (1999). Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 189, 358-362.
50. Damjanovich J, Adány R, Berta A, Beck Z, and Balázs M (2000). Mutation of the RB1 gene caused unilateral retinoblastoma in early age. Cancer Genet Cytogenet 119, 1-7.
51. Cook KM and Figg WD (2010). Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60, 222-243.
52. Chen H-Z, Tsai S-Y, and Leone G (2009). Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 9, 785-797.
53. Nowling T, Bernadt C, Johnson L, Desler M, and Rizzino A (2003). The co-activator p300 associates physically with and can mediate the action of the distal enhancer of the FGF-4 gene. J Biol Chem 278, 13696-13705.
54. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, and Zhao K (2009). Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138, 1019-1031.
55. Visel A, Blow MJ, Li Z, Zhang T, Akiyama JA, Holt A, Plajzer-Frick I, Shoukry M, Wright C, Chen F, et al. (2009). ChIP-seq accurately predicts tissuespecific activity of enhancers. Nature 457, 854-858.
56. Gabellini C, Del Bufalo D, and Zupi G (2006). Involvement of RB gene family in tumor angiogenesis. Oncogene 25, 5326-5332.
57. Pillai S, Kovacs M, and Chellappan S (2010). Regulation of vascular endothelial growth factor receptors by Rb and E2F1: role of acetylation. Cancer Res 70, 4931-4940.
58. Rossler J, Dietrich T, Pavlakovic H, Schweigerer L, Havers W, Schuler A, Bornfeld N, and Schilling H (2004). Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol 164, 391-394.
59. Zaghloul MS, El-Naggar M, El-Deeb A, Khaled H, and Mokhtar N (2000). Prognostic implication of apoptosis and angiogenesis in cervical uteri cancer. Int J Radiat Oncol Biol Phys 48, 1409-1415.
60. Lucchi M, Mussi A, Fontanini G, Faviana P, Ribechini A, and Angeletti CA (2002). Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 21, 1105-1110.
61. Mikulić D, Ilić I, Cepulić M, Orlić D, Giljević JS, Fattorini I, and Seiwerth S (2004). Tumor angiogenesis and outcome in osteosarcoma. Pediatr Hematol Oncol 21, 611-619.
62. Stengel KR, Thangavel C, Solomon DA, Angus SP, Zheng Y, and Knudsen ES (2009). Retinoblastoma/p107/p130 pocket proteins: protein dynamics and interactions with target gene promoters. J Biol Chem 284, 19265-19271.